CRL
Charles River Laboratories
294.40$
+6.2%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 64.8% | 64.1% | 65.9% | 65.5% | 65.4% | 71.6% | 67.7% | 65.4% | 66.3% | 69.0% | 72.0% | 63.8% | 67.8% | |
| 35.2% | 35.9% | 34.1% | 34.5% | 34.6% | 28.4% | 32.3% | 34.6% | 33.7% | 31.0% | 28.0% | 36.2% | 32.2% | |
| 17.2% | 19.5% | 18.4% | 16.5% | 19.7% | 19.5% | 18.1% | 18.6% | 17.7% | 18.9% | 16.0% | 22.8% | 18.8% | |
| 20.5% | 22.8% | 21.6% | 19.7% | 22.9% | 45.1% | 24.7% | 24.9% | 20.4% | 18.9% | 16.0% | 24.2% | 19.9% | |
| 14.8% | 13.1% | 12.5% | 14.8% | 11.6% | -16.7% | 7.6% | 9.7% | 13.3% | 12.1% | 12.0% | 11.9% | 12.3% | |
| 3.3% | 3.3% | 3.5% | 3.2% | 3.0% | 2.8% | 2.8% | 2.9% | 2.5% | 2.4% | 2.7% | 3.0% | 2.7% | |
| 11.0% | 20.6% | 9.8% | 11.7% | 9.0% | -21.6% | 3.7% | 6.9% | 8.7% | -29.6% | -3.0% | 5.3% | -4.6% | |
| 2.4% | 1.9% | 2.4% | 2.5% | 2.1% | -0.3% | 1.0% | 1.8% | 3.1% | -1.8% | -1.5% | 5.4% | 1.3% | |
| 8.5% | 18.5% | 6.7% | 8.8% | 6.8% | -21.5% | 2.6% | 5.1% | 5.4% | -27.8% | -1.5% | -0.1% | -6.0% | |
| 22.0% | 31.8% | 21.7% | 23.2% | 20.8% | -8.6% | 18.7% | 21.4% | 19.7% | -19.3% | 6.4% | 15.0% | 5.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.